Abstract：
BACKGROUND:Little is known about the prognostic factors of acute liver enzyme variations in HIV-hepatitis B virus (HBV)-coinfected patients. OBJECTIVES:To identify prognostic factors of acute liver enzyme abnormalities in HIV-HBV-coinfected patients with a focus on the putative role of antiretroviral drugs. DESIGN:Data from a 3-year, prospective, multicentre cohort study involving HIV-HBV patients were used. METHODS:A Markov model was used to identify prognostic factors of acute episodes of cytolysis and cholestasis in 300 HIV-HBV-coinfected patients. The effect of antiretroviral therapy was analysed according to the classes of drugs, duration of treatment and treatment modifications. RESULTS:The incidence rates of acute episodes of cytolysis and cholestasis were 13.4 per 100 patient-years (95% confidence interval [CI] 9.5-17.3) and 7.1 per 100 patient-years (95% CI 4.2-10.0), respectively (median follow up 34.1 months). Independent risk factors for cytolysis were a high level of HBV or HIV replication, as well as a low of CD4+ T-cell count. No antiretroviral drug was associated with cytolysis, whereas protease inhibitors seemed to be independently associated with cholestasis, along with treatment modifications and the duration of HIV infection. CONCLUSION:Acute and reversible episodes of cytolysis or cholestasis were common and associated with virus- and host-related determinants. The choice of the optimal antiretroviral combination in HIV-HBV-coinfected patients must take into account the necessity of exerting an efficient control of HIV and HBV replication (associated with transient cytolysis) and the risk of inducing cholestasis (associated with the use of protease inhibitors and treatment modifications).
journal_name
Antivir Therjournal_title
Antiviral therapyauthors
Chauvel O,Lacombe K,Bonnard P,Lascoux-Combe C,Molina JM,Miailhes P,Girard PM,Carrat Fsubject
Has Abstractpub_date
2007-01-01 00:00:00pages
1115-26issue
7eissn
1359-6535issn
2040-2058journal_volume
12pub_type
杂志文章,多中心研究abstract：BACKGROUND:Serum HBV RNA is detectable during nucleoside/nucleotide analogue therapy as a result of unaffected RNA replicative intermediates or interrupted reverse transcription. We studied the predictive value of serum HBV RNA for initial virological response during nucleoside analogue therapy. METHODS:Serum HBV RNA ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2777
更新日期：2015-01-01 00:00:00
abstract：BACKGROUND:The objective of this study was to compare indinavir peak plasma (Cmax) values after administration of indinavir/ritonavir 800/100 mg on an empty stomach or with food. High indinavir Cmax values have been associated with indinavir-related nephrotoxicity. METHODS:This was an open-label, randomized, two-treat...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：2003-08-01 00:00:00
abstract：:There are many potential reasons for increased liver-related mortality in HIV-hepatitis B virus (HBV) coinfection compared with either infection alone. HIV infects multiple cells in the liver and might potentially alter the life cycle of HBV, although evidence to date is limited. Unique mutations in HBV have been defi...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：
更新日期：2009-01-01 00:00:00
abstract：BACKGROUND:Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS:Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,多中心研究
doi：
更新日期：2006-01-01 00:00:00
abstract：BACKGROUND:Peripheral neuropathy (PN) in HIV-infected individuals is thought be due to a toxic effect on mitochondria induced by some nucleoside reverse transcriptase inhibitors (NRTI). METHODS:A time-to-event analysis was performed using data from the Delta trial to study the incidence of PN in HIV-infected individua...
journal_title：Antiviral therapy
pub_type： 杂志文章,随机对照试验
doi：
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:The tendency for haemorrhagic stroke in patients with chronic HCV infection has emerged recently but the finding may be confounded by comorbidities. Proving the causality between HCV infection and haemorrhagic stroke is mandatory. Our study was designed to investigate the incidence of intracranial haemorrhag...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3172
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND:Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lamb...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2009-01-01 00:00:00
abstract：BACKGROUND:Zidovudine (3'-azido-3'-deoxythymidine, AZT), administered to pregnant women alone or in combination with other antiretroviral drugs, greatly reduces the mother-to-child transmission of HIV-1. The potential genotoxicity of these molecules is underestimated and wide-ranging evaluation of its biological and cl...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:Longitudinal assessment of liver fibrosis with transient elastometry (TE) in patients with chronic viral hepatitis is becoming routine clinical practice in many clinics, as this procedure is non-invasive, easy to perform and relatively inexpensive, allowing early detection of cirrhosis. Herein, we examine th...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1630
更新日期：2010-01-01 00:00:00
abstract：:Delayed and variable antibody responses to HCV make it difficult to diagnose acute HCV infection reliably. Immunoglobulin (Ig)M and IgG anti-HCV may be observed simultaneously as disease persists. IgM plays a key role in mixed cryoglobulinemia (MC), an immune complex disease strongly associated with persistent HCV inf...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：10.3851/IMP2222
更新日期：2012-01-01 00:00:00
abstract：:The use of nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of HIV infection is clearly linked to the development of subcutaneous fat atrophy. Until recently, however, in vitro studies of adipocytes have shown no or only modest and inconsistent effects of these agents on adipocyte biology. This is...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2006-01-01 00:00:00
abstract：BACKGROUND:Nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs) cause side effects in some patients, prompting the use of either partly or fully NRTI-sparing regimens. METHODS:We used data from the Swiss HIV Cohort Study to estimate the effectiveness of two new dolutegravir dual regimens relative to the...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3310
更新日期：2019-01-01 00:00:00
abstract：BACKGROUND:Insulin resistance (IR) was one of the first reported complications in HIV-positive patients who were receiving antiretroviral therapy (ART). However, the metabolic effects of newer fixed-dose ART combinations are unclear. METHODS:This Phase I prospective randomized open-label study evaluated the effects on...
journal_title：Antiviral therapy
pub_type： 杂志文章,随机对照试验
doi：10.3851/IMP3049
更新日期：2016-01-01 00:00:00
abstract：BACKGROUND:A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therap...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,多中心研究,随机对照试验
doi：10.3851/IMP3169
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND:Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations. METHODS:Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant t...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章
doi：10.3851/IMP1780
更新日期：2011-01-01 00:00:00
abstract：:HCV-related liver disease is an important contributor to morbidity and mortality in the HIV-infected population. Successful treatment of HIV-HCV-coinfected patients is followed by favourable clinical outcomes. While the combination of pegylated interferon and ribavirin remains the mainstay in the treatment of non-1 HC...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：10.3851/IMP2601
更新日期：2013-01-01 00:00:00
abstract：:Zalcitabine (ddC) is a nucleoside analogue reverse transcriptase inhibitor with demonstrated clinical benefit in combination use. More widespread use of zalcitabine has been limited by a number of factors including peripheral neuropathy and three times daily dosing. However, screening for the risk factors for peripher...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：
更新日期：1998-01-01 00:00:00
abstract：:Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：
更新日期：2001-09-01 00:00:00
abstract：BACKGROUND:HIV type-1 (HIV-1) has been shown to be frequently transmitted by acutely infected patients. We investigated the relationship between the dynamics of HIV-1 transmission within recently infected patients, the HIV-1 variability and the transmission of antiretroviral drug resistance. METHODS:We included patien...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2009-01-01 00:00:00
abstract：BACKGROUND/AIMS:The role of antibody in hepatitis C virus (HCV) infection remains unclear although many reports attest to its role in viral clearance. Here we describe epitopes that are recognized by antibody present in the serum of infected patients and show that such epitopes can induce neutralizing antibodies. METH...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2006-01-01 00:00:00
abstract：:HIV-HBV-coinfected patients require optimal control of viral replication in order to prevent the development of severe comorbidities, such as liver cirrhosis and hepatocellular carcinoma. The genetic diversity of HBV is a poorly investigated factor of such viral replication in HIV-infected hosts. HBV genome diversity ...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：10.3851/IMP1495
更新日期：2010-01-01 00:00:00
abstract：:The aim of this study (the RESCUE trial) was to verify the effect of a shift from a lamivudine-containing to a didanosine-containing regimen on viral replication in HIV-1-infected subjects who had experienced prior treatment failure. Sixteen patients (didanosine-experienced in 14/16 cases) were consecutively enrolled:...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2001-03-01 00:00:00
abstract：:Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in China, diagnostic methods have evolved. Despite definitive diagnoses, SFTS management has focused on prevention and supportive care. Although conservative treatment is effective for mild cases, there is an urgent need for an effective ther...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3036
更新日期：2016-01-01 00:00:00
abstract：BACKGROUND:No data are available on the clinical presentation and virological pattern in the case of failure of interferon (IFN)-free regimens in patients with genotype-3h. In this paper authors identified the virological and clinical characteristics of patients with genotype-3h treated with suboptimal or not indicated...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3228
更新日期：2018-01-01 00:00:00
abstract：:A 14 year old common variable immunodeficiency patient developed severe protein-losing enteropathy. A chronic enteral infection with human parechovirus type 1 and norovirus was diagnosed. Treatment strategies aimed at virus eradication and providing supportive care were ineffective. The antipicornavirus agent pleconar...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1792
更新日期：2011-01-01 00:00:00
abstract：OBJECTIVE:To assess the baseline factors associated with haematological toxicity that lead to ribavirin or pegylated interferon (peginterferon) dosage reductions in hepatitis C and human immunodeficiency virus (HCV/HIV)-coinfected patients. DESIGN:Multicentre, prospective, observational study. SETTING:Eleven hospital...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,多中心研究
doi：
更新日期：2005-01-01 00:00:00
abstract：BACKGROUND:We examined the prevalence of ritonavir-boosted darunavir (DRV) resistance-associated mutations (RAMs) in HIV-infected children in the UK to determine the drug's potential clinical utility as a first-line or second-line protease inhibitor (PI). METHODS:The prevalence of DRV RAMs, identified from IAS 2010 an...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2015
更新日期：2012-01-01 00:00:00
abstract：:To our knowledge, there are no previously published cases of enteroviral infection complicated by pityriasis lichenoides et varioliformis acuta (PLEVA). A 30-year-old woman is reported with a severe form of PLEVA, preceded by hand, foot and mouth disease. Immunosuppressive treatment with cyclosporin A resulted in rapi...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3012
更新日期：2016-01-01 00:00:00
abstract：BACKGROUND:The combination of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is the standard of care for hepatitis C virus (HCV) treatment in HIV-coinfected individuals. In 2007, abacavir (ABC)-based antiretroviral therapy was, for the first time, reported to be associated with early virological failure during HCV...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:Lamivudine is widely used in patients with chronic hepatitis B virus (HBV) infection. In cirrhotic patients, long-term lamivudine therapy significantly reduced the risk of hepatocellular carcinoma (HCC). However, in a small but substantial portion of patients, HCC still developed despite lamivudine therapy. ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2009-01-01 00:00:00
